^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Allocetra (HLA-matched donor mononuclear enriched leukocytes)

    i
    Other names: leukocyte stem cell therapy, autologous apoptotic cell-based therapy, non-HLA-matched allogeneic peripheral blood mononuclear cells
    Associations

    News

    Trials
    Company:
    Enlivex Therap
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    8d
    ENX-CL-05-002: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter nStudy of Intra-Articular Allocetra in Participants with Primary Knee nOsteoarthritis. (2025-524668-39-00)
    P1/2, N=75, Not yet recruiting, Enlivex Therapeutics Ltd.
    New P1/2 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    10d
    Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, Kaplan Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Apr 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    10d
    ENX-CL-06-001: Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=5, Terminated, Enlivex Therapeutics Ltd. | Trial completion date: Sep 2026 --> Apr 2026 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Oct 2025; reprioritization
    Trial completion date • Trial termination • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    2ms
    ENX-CL-05-001: A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis (2023-508748-23-00)
    P1/2, N=156, Completed, Enlivex Therapeutics Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    4ms
    ENX-CL-05-001: Study of Intra-articular Allocetra in Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=160, Active, not recruiting, Enlivex Therapeutics Ltd. | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    8ms
    A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients (clinicaltrials.gov)
    P2, N=148, Completed, Enlivex Therapeutics Ltd. | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    8ms
    ENX-CL-06-001: Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=6, Recruiting, Enlivex Therapeutics Ltd. | Trial completion date: Jan 2026 --> Sep 2026
    Trial completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    9ms
    ENX-CL-05-001: Study of Intra-articular Allocetra in Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=160, Active, not recruiting, Enlivex Therapeutics Ltd. | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    12ms
    ENX-CL-05-001: Study of Intra-articular Allocetra in Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=160, Active, not recruiting, Enlivex Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    over1year
    ENX-CL-06-001: Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=6, Recruiting, Enlivex Therapeutics Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    over1year
    Apoptotic Cell-Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock. (PubMed, Mil Med)
    In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell-based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    over1year
    Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Enlivex Therapeutics Ltd.
    New P1 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)